GE HealthCare spotlights its innovation renaissance designed to advance precision care at ECR 2026

• The company will showcase seven of its most significant innovations across Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Mammography, Molecular Imaging, SPECT/CT, and Image Guided Therapy.
• Supported by more than $5.1 billion in innovation investment, GE HealthCare is advancing precision care globally1. The company does so through purpose‑built, cloud‑ and AI‑enabled technologies designed to address real clinical and operational challenges and help deliver better patient outcomes.

Vienna – March 4, 2026 - GE HealthCare (Nasdaq: GEHC) will showcase seven of its most significant innovations at ECR 2026, designed to help healthcare providers respond to growing demand, rising clinical complexity, and persistent operational pressure - without compromising quality of care. Healthcare providers worldwide continue to face workforce constraints and increasing imaging volumes; in response, GE HealthCare is advancing AI‑enabled and cloud‑based technologies intended to help turn data into actionable insights, streamline workflows, and support more efficient operations.

The company’s ECR 2026 theme, “Our Boldest Ideas Yet,” reflects its deliberate approach to innovation. GE HealthCare is focused on developing technologies shaped by close collaboration with clinicians and designed to deliver tangible clinical and operational value - supporting precise diagnoses, personalized care decisions, and efficiency across care settings.

Elie Chaillot, President and CEO of GE HealthCare International, added “Our commitment to delivering the future of healthcare is focused on delivering innovations that empower clinicians, drive efficiencies, and help improve patient lives. We’re thrilled to be showcasing some of our biggest and boldest ideas yet at ECR 2026 and look forward to collaborating with our customers to enhance care for patients globally.”

Seven transformative innovations

At ECR 2026, GE HealthCare will highlight seven of its most transformative innovations - each intended to advance imaging performance, operational efficiency, and diagnostic confidence across modalities; ultimately helping clinicians improve patient outcomes.

These new products are a direct result of the company’s $5.1 billion innovation investment since its spin-off in 20231.

• Omni 128cm total body PET/CT
  A next-generation imaging system designed to advance precision care as well as cancer diagnosis, staging and treatment planning. Built for both clinical and research excellence, the system may support the development and evaluation of new clinical pathways, novel PET tracers and emerging theranostic agents. Omni 128cm is CE marked and available for sale in EU countries. Not approved or cleared by the U.S. FDA. Not available in all markets.
  
  
• StarGuide™ GX, digital 4D SPECT/CT
  Designed with excellent precision, clinical efficiency and impressive versatility, StarGuide GX empowers personalized care and research innovation as nuclear medicine expands into new applications. It is CE marked, and not cleared or approved by the U.S. FDA, not available for sale in the United States.
  
  
• Photonova™ Spectra 
  The first in the next generation of spectral counting CT systems with 8-bins of energy resolution, powered by GE HealthCare’s proprietary Deep Silicon detector technology. Designed for impact across specialties, it is intended to support neurological and oncological assessments, comprehensive musculoskeletal and thoracic imaging and detailed cardiac exams. It is 510(k) pending with the U.S. FDA, not CE marked, not available for sale.
  
  
• Next-generation SIGNA MRI technology designed to enhance precision diagnosis for clinicians, these innovations include:

• SIGNA™ Sprint with Freelium™ is a sealed configuration of SIGNA™ Sprint Select, a new 1.5T sealed magnet system, that designed to combine a sustainable design with uncompromised image quality, and operational autonomy to expand access to advanced MR, even in remote settings.  SIGNA Sprint Select is 510(k) cleared by the U.S. FDA, not CE marked, not available for sale in all regions.
• SIGNA™ Bolt , a new 3T MRI scanner, is engineered to support precision diagnostics, clinical efficiency, and advanced research capability. SIGNA Bolt is 510(k) cleared by the U.S. FDA, not CE marked, not available for sale in all regions.
• Both are powered by SIGNA™ One, an ecosystem of AI-driven workflow solutions designed to reduce inefficiencies and support MRI exams from plan to scan and beyond. SIGNA One represents features and content that are 510(k) cleared with SIGNA Bolt and SIGNA Sprint with Freelium by the U.S. FDA, not CE marked, not available for sale in all regions.

• Pristina™ Recon DL
  This solution is GE HealthCare's advanced 3D mammography image reconstruction technology - the first in mammography to combine deep learning with iterative reconstruction to provide outstanding digital breast tomosynthesis (DBT) image without compromising on patient dose. The Pristina Via with Recon DL mammography system offers high clinical confidence and efficient workflows with exceptional patient experience. Pristina Recon DL is CE marked and available for sale in the EU and U.S. (Premarket Authorization approved).
  
  
• Allia™ Moveo
  The latest Allia platform assists clinicians in a wide range of cardiovascular, vascular, non-vascular, interventional and surgical procedures. Allia Moveo delivers enhanced workflow through a compact, cable-free C-arm system with an intuitive user interface and AI-powered guidance tools to help clinicians work efficiently and adapt to the spatial constraints of traditional interventional suites. Allia Moveo is CE marked and available for sale in the EU and U.S. 510(k) cleared.
  
  
• The next generation of LOGIQ™ general imaging ultrasound systems
  An intelligently designed portfolio built to elevate clinical imaging, accelerate workflows, and unlock deeper diagnostic insight. Equipped with advanced imaging capabilities, enhanced AI-powered automation, and an expanded open digital platform, the latest LOGIQ systems are engineered to simplify daily practice while supporting more confident, informed clinical decisions. The latest LOGIQ ultrasound systems are CE marked and available for sale in the EU and U.S. 510(k) cleared. 

A defining moment for the future of radiology

GE HealthCare’s new wave of innovation reflects a vision for a future of healthcare that is more connected, efficient, and precise - helping clinicians deliver more personalized care and ultimately helping to improve patient outcomes.

Visit the GE HealthCare booth at ECR 2026 on Level 0, Area F at the Austria Center Vienna, and discover more on our event page.